Core Viewpoint - The announcement details the pledge and release of shares by the controlling shareholder of Guizhou Yibai Pharmaceutical Co., Ltd., indicating a total of 21,000,000 shares pledged, which represents 11.32% of the shareholder's holdings and 2.65% of the company's total shares [2][7]. Share Pledge Situation - Controlling shareholder Dou Qiling holds 185,457,636 shares, accounting for 23.42% of the company's total shares [2]. - The total number of pledged shares by Dou Qiling and her concerted action person Dou Yaqi is 21,000,000 shares, which is 11.31% of their combined holdings and 2.65% of the company's total shares [2]. Release of Pledged Shares - The announcement confirms that the pledged shares are not used for major asset restructuring performance compensation or other guarantees [3]. - The company will disclose any future use of the released shares for other pledge activities [5]. Shareholder Pledge Summary - As of the announcement date, the total pledged shares by the controlling shareholder and concerted action persons are detailed, with a note on rounding differences in data [6]. Future Pledge Outlook - Dou Qiling has no shares maturing in the next six months, and the total shares maturing within the next year (excluding those maturing in six months) is 21,000,000 shares, which is 11.32% of her total holdings and 2.65% of the company's total shares [7]. - Dou Qiling's credit status is good, and she has the financial capability to repay, with funds sourced from her own and self-raised funds [8]. - There are no risks of forced liquidation, and the pledge and release of shares will not affect the company's operations or governance, nor will it lead to a change in actual control [8].

重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量（含本次质押和解除质押）为 21,000,000 股，占其持股 数量的 11.32%，占公司总股本的 2.65%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量（含本 次质押和解除质押）为 21,000,000 股，占窦啟玲女士及其一致行动人窦雅琪女 士合计所持公司股份的 11.31%，占公司总股本的 2.65%。 证券代码：600594 证券简称：益佰制药 公告编号：2025-039 贵州益佰制药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，公司获悉控股股东窦啟玲女士将所持有的本公司部分股份办理了股 票质押及解除质押业务，具体情况如下： 注：以上数据因四舍五入原因导致数据在尾数上略有差异。 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障 ...

Core Viewpoint - The announcement from Yibai Pharmaceutical indicates that the controlling shareholder, Dou Qiling, has engaged in partial share pledges and releases, which are primarily aimed at debt repayment and do not pose a risk to the company's operations or control [1] Group 1: Share Pledge Details - Dou Qiling pledged 21 million shares to Guotai Junan Securities, representing 11.32% of her holdings and 2.65% of the total share capital, for debt repayment, starting from November 26, 2025, and maturing on November 26, 2026 [1] - On November 27, 2025, Dou Qiling will release 22.6683 million shares from pledge, which accounts for 12.22% of her holdings and 2.86% of the total share capital [1] - The total pledged shares by Dou Qiling and her concerted parties amount to 21 million shares, representing 11.31% of their combined holdings and 2.65% of the total share capital [1] Group 2: Risk Assessment - The company assesses that the risk associated with the pledged shares is manageable and will not affect its operations or control [1]

Group 1 - The board of directors of Guizhou Yibai Pharmaceutical Co., Ltd. held its 15th meeting of the 8th session on November 26, 2025, to address urgent matters, waiving the notice period as per company regulations [2][5] - All 7 directors attended the meeting, which was chaired by Chairwoman Dou Qiling [3][4] - The meeting was compliant with the Company Law and the company's articles of association [5] Group 2 - The board approved the proposal to supplement the independent director position, following the resignation of independent director Chen Yisong due to personal reasons [6] - Liang Liang was elected as the new independent director and will also serve as the chair of the audit committee, a member of the nomination committee, and a member of the remuneration and assessment committee [6] - Liang Liang holds a PhD in management from Tohoku University, Japan, and is currently an associate professor at Guizhou University, with no prior shareholding in the company [8]

Group 1 - The core point of the article is that Yibai Pharmaceutical (SH 600594) held a temporary board meeting on November 26, 2025, to discuss the addition of members to its specialized committee [1] - For the year 2024, Yibai Pharmaceutical's revenue composition is as follows: 77.44% from pharmaceutical manufacturing, 21.46% from medical services, and 1.1% from other businesses [1] - As of the report date, Yibai Pharmaceutical has a market capitalization of 3.3 billion yuan [1]

北京市君致律师事务所 关于贵州益佰制药股份有限公司 2025 年第二次临时股东会 法 律 意 见 书 北京 · 东城区北三环东路 36 号环球贸易中心 B 座 11 层 100013 电话（Te1）: 010-52213236/52213237/52213238/52213239 ्Ӣᐸੑ㠪ᗁᐾӁࣗᡶ ީӄ䍫ᐔⴀ֦㦥㛗Գᴿ䲆ޢਮ ᵜ㿱Җᡰᴹᮠ٬؍⮉єսሿᮠˈ㤕ࠪ⧠ᙫᮠо࠶亩ᮠ٬ѻ઼нㅖⲴᛵ ഐᡰ㠤DŽޕѪഋ㠽ӄˈ൷ߥ ᵜᡰᖻᐸṩᦞޣ⌅ᖻǃ⌅㿴઼㿴㤳ᙗ᮷ԦⲴ㾱≲ˈ᤹➗ᖻᐸ㹼ъޜ䇔Ⲵ ъ࣑ḷ߶ǃ䚃ᗧ㿴㤳઼औࣹቭ䍓㋮⾎ˈࠪާ⌅ᖻ㿱ྲл˖ жȽᵢ⅗㛗ђՐⲺਢ䳼Ƚਢᔶぁᓅ ˄а˅㓿ᵜᡰᖻᐸṨḕˈޜਨҾ ᒤ ᴸ ᰕਜᔰⲴㅜޛቺ㪓һՊㅜ 1 ᒪㅢӂ⅗Ѫᰬ㛗ђՐ ⌋ᗁᝅ㿷Ҝ 㠪φ䍫ᐔⴀ֦㦥㛗Գᴿ䲆ޢਮ ेӜᐲੋ㠤ᖻᐸһ࣑ᡰ˄ԕлㆰ〠Āᵜᡰā˅᧕ਇ䍥ᐎ⳺֠ࡦ㦟㛑ԭᴹ䲀ޜ ਨԕлㆰ〠Ā⳺֠ࡦ㦟āᡆĀޜਨā Ⲵငᢈˈᤷ⍮ᖻᐸࠪᑝ⳺֠ࡦ㦟 ᒤ ㅜҼ⅑Ѥᰦ㛑ьՊ˄ԕлㆰ〠Āᵜ⅑㛑ьՊā˅DŽṩᦞljѝॾӪ≁ޡ઼ഭ䇱ࡨ⌅NJ ԕлㆰ〠Ālj䇱ࡨ⌅NJā ǃljѝॾӪ≁ޡ઼ഭޜਨ⌅NJԕлㆰ〠Āljޜਨ⌅NJā ઼ljкᐲޜਨ㛑ьՊ㿴ࡉN ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-037 贵州益佰制药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 26 日 (二)股东会召开的地点：贵州益佰制药股份有限公司行政楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长窦啟玲女士主持，会议采用现场投票 与网络投票相结合的方式进行表决，本次会议的召集、召开和表决方式符合《公 司法》及《公司章程》的有关规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席7人； 2、公司董事会秘书出席会议；公司其他高管列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：《关于增补公司独立董事的议案》 审议结果：通过 表决情况： | 1、出席会议 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-038 3、公司全体高管列席了会议。 4、本次会议的召集和召开符合《公司法》及《公司章程》等相关规定。 二、董事会会议审议情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、贵州益佰制药股份有限公司（以下简称"公司"）第八届董事会第十五 次会议通知于 2025 年 11 月 26 日以电子邮件等方式送达全体董事及高管，本次 会议于 2025 年 11 月 26 日在公司行政楼会议室以现场加通讯会议方式召开。因 情况紧急，公司需要尽快召开董事会临时会议,根据《公司章程》和《公司董事 会议事规则》等相关规定,本次董事会会议豁免通知时限要求，召集人在会议上 作出了说明。 2、本次会议应出席董事 7 人，实际出席董事 7 人。本次会议由董事长窦啟 玲女士召集和主持。 贵州益佰制药股份有限公司 第八届董事会第十五次会议决议公告 特此公告。 本次会议以记名投票表决方式通过了如下议案： 贵州益佰制药股份有限公司董事会 2025 年 11 月 27 ...

Group 1 - The third Chengdu-Chongqing dual-city social medical personnel comprehensive skills competition concluded in Chengdu, with Yibai Pharmaceutical Mianyang Fulin Hospital winning the "Group First Prize" and ranking among the top 15 in Sichuan Province [1] - The participating team from Yibai Pharmaceutical Mianyang Fulin Hospital prepared extensively, achieving awards in various categories, including third prize in the "Three Basics and Three Stricts Theory Knowledge Competition" and excellence awards in both the "Adult Cardiopulmonary Resuscitation Skills Competition" and "Health Science Popularization Competition" [1] - The competition provided an opportunity for Yibai Pharmaceutical Mianyang Fulin Hospital to enhance clinical team collaboration and overall technical capabilities, showcasing the professional standards and progressive spirit of social medical institutions [1] Group 2 - Yibai Pharmaceutical Mianyang Fulin Hospital is a key component of Yibai Pharmaceutical's "One Ship and Two Wings" strategic layout, relying on the group's deep integration of industry and medical resources [2] - The hospital has consistently achieved excellent results in various national, provincial, and municipal competitions by strengthening talent training and specialty construction [2] - The hospital aims to leverage the competition experience to enhance its medical service capabilities and contribute to the high-quality development of social medicine in the Chengdu-Chongqing region [2]

2025年第二次临时股东会会议资料 1/5 贵州益佰制药股份有限公司 2025 年第二次临时股东会会议资料 贵州益佰制药股份有限公司 600594 目录 | 贵州益佰制药股份有限公司 2025 年第二次临时股东会会议议程 3 | | --- | | 议案一：《关于增补公司独立董事的议案》 4 | 2/5 贵州益佰制药股份有限公司 2025 年第二次临时股东会会议资料 贵州益佰制药股份有限公司 2025 年第二次临时股东会会议资料 贵州益佰制药股份有限公司 2025 年第二次临时股东会会议议程 会议方式：本次股东会采用现场投票和网络投票相结合的方式召开 现场会议时间：2025年11月26日 星期三 10:00 交易系统投票平台投票时间：2025年11月26日 星期三 9:15-9:25，9:30- 11:30，13:00-15:00 互联网投票平台投票时间：2025年11月26日 星期三 9:15-15:00 现场会议地点：贵州益佰制药股份有限公司行政楼会议室 召集人：贵州益佰制药股份有限公司董事会 出席对象：截止2025年11月19日下午交易结束后在中国证券登记结算有限责任公 司上海分公司登记在册的本公司股东 ...